- Financing co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners with significant participation from other new and existing investors

- 由Frazier Life Sciences和Venrock Healthcare Capital Partners共同领投融资，其他新老投资者也积极参与

- Proceeds will support the ongoing clinical development of AGA2118, AGA2115, AGA111, and other pipeline assets

- 收益将支持AGA2118、AGA2115、AGA111及其他管线资产的持续临床开发。

- Kevin Li, M.D., from Frazier Life Sciences will join the Board of Directors

- 来自Frazier Life Sciences的Kevin Li博士将加入董事会

Westlake Village,

西湖村，

California, USA

美国加利福尼亚州

, February 5, 2026

2026年2月5日

– Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health, today announced the closing of a $130 million Series D financing round. Frazier Life Sciences and Venrock Healthcare Capital Partners co-led the financing, with participation from new investors: Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management, and Wellington Management.

– Angitia生物制药公司（“Angitia”或“公司”），一家临床阶段的生物技术公司，致力于开发改善肌肉骨骼健康的新疗法，今天宣布完成了1.3亿美元的D轮融资。本轮融资由Frazier生命科学和Venrock医疗资本伙伴共同领投，新投资者包括Ascenta资本、由Blackrock管理的某些基金和账户、BVF Partners、Logos资本、RA资本管理以及Wellington管理。

Existing investors, Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital and Yonghua Capital, also participated. Proceeds from the Series D will support the continued development of Angitia’s robust pipeline of novel, differentiated investigational treatments for serious musculoskeletal diseases..

现有投资者贝恩资本生命科学、Elikon Venture、骏利亨德森投资、3H健康投资、高瓴投资、君联资本、晨兴集团、奥博资本、TF Capital和永华资本也参与了本轮投资。D轮融资所得将用于支持安蒂亚强大的严重肌肉骨骼疾病新型差异化研究治疗管道的持续开发。

“This financing underscores the continued growth of Angitia, the quality of our emerging data, and the advancement of our clinical product candidates, as recently demonstrated with the completion of enrollment in our Phase 2 ARTEMIS trial in postmenopausal osteoporosis and the initiation of dosing in our Phase 2 IDUN trial in osteogenesis imperfecta,” said Dr.

“这笔融资突显了Angitia的持续增长、我们新兴数据的质量以及我们临床候选产品的进展，正如我们最近在绝经后骨质疏松症的二期ARTEMIS试验中完成入组，并在成骨不全症的二期IDUN试验中开始给药所证明的那样，”博士表示。

David Ke, M.D., Chief Executive Officer of Angitia. “We are excited and grateful to add another strong set of high-quality investors to our growing syndicate.”.

大卫·柯，医学博士，Angitia首席执行官。“我们感到兴奋并感激能够为我们的不断壮大的财团增加另一组高质量的投资者。”

In connection with the financing, Kevin Li, M.D., a Partner on the Frazier Life Sciences team, will join the Board of Directors. Dr. Li was previously a resident physician in Internal Medicine at Stanford University and a consultant at McKinsey & Company, where he focused on corporate strategy, growth and M&A in the hospital services and pharmaceutical industries.

与此次融资相关，Frazier Life Sciences 团队的合伙人 Kevin Li 医学博士将加入董事会。李博士此前曾是斯坦福大学的内科住院医师，并在麦肯锡公司担任顾问，专注于医院服务和制药行业的企业战略、增长及并购业务。

Dr. Li received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa..

李博士在斯坦福大学获得医学博士学位，在耶鲁大学获得理学学士学位，他在分子生物物理学和生物化学专业以最高荣誉毕业，并且是 Phi Beta Kappa 荣誉学会的成员。

About Angitia Biopharmaceuticals

关于Angitia生物制药公司

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health. Angitia is currently developing three biologic product candidates (AGA2118, AGA2115 and AGA111) in the clinic for the treatment of postmenopausal osteoporosis, osteogenesis imperfecta and spinal fusion.

安吉提亚生物制药是一家临床阶段的生物技术公司，致力于开发改善肌肉骨骼健康的新疗法。安吉提亚目前正在临床中开发三种生物制品候选产品（AGA2118、AGA2115 和 AGA111），用于治疗绝经后骨质疏松症、成骨不全和脊柱融合。

Leveraging the team's extensive experience and scientific acumen in bone biology and musculoskeletal drug development, Angitia is committed to developing novel therapeutics based on rational biology and clearly defined unmet medical needs..

利用团队在骨骼生物学和肌肉骨骼药物开发方面的丰富经验和科学智慧，Angitia致力于基于合理的生物学和明确的未满足医疗需求开发新型疗法。

Globe Newswire:

全球新闻网：

https://www.globenewswire.com/news-release/2026/02/05/3232886/0/en/Angitia-Biopharmaceuticals-Announces-130-Million-Series-D-Financing.html

https://www.globenewswire.com/news-release/2026/02/05/3232886/0/en/Angitia-Biopharmaceuticals-宣布-1.3-亿美元-D轮融资.html

Learn more at

了解更多信息，请访问

www.angitiabio.com

www.angitiabio.com

.

。

Investor & Media Contact:

投资者和媒体联系人：

William Windham

威廉·温德姆

Solebury Strategic Communications

索尔伯里战略传播

wwindham@soleburystrat.com

wwindham@soleburystrat.com

646-378-2946

646-378-2946

Forward-Looking Statements

前瞻性声明

This press release is prepared by Angitia Biopharmaceuticals (the “Company”, “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “continue”, “could”, “potential”, “may”, “will”, “goal” or similar expressions and the negatives of those terms.

本新闻稿由Angitia生物制药公司（“公司”，“我们”）编写，仅供参考。前瞻性声明包括所有非历史事实的声明，在某些情况下，可以通过“预期”、“预计”、“打算”、“计划”、“相信”、“继续”、“可能”、“潜在”、“或许”、“将”、“目标”或类似表达及这些词语的否定形式来识别。

However, not all forward-looking statements contain these identifying words..

然而，并非所有前瞻性声明都包含这些标志性词语。

These forward-looking statements involve substantial known and unknown risks and uncertainties, including the risk that results in earlier clinical trials and preclinical studies may not be indicative of future results and that any product candidates may not ultimately obtain required approvals or meaningfully improve patient outcomes, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements.

这些前瞻性陈述涉及大量的已知和未知的风险和不确定性，包括早期临床试验和临床前研究的结果可能无法预示未来结果的风险，以及任何候选产品最终可能无法获得必要批准或显著改善患者预后的风险，以及其他超出公司控制范围、难以预测的因素，可能导致我们的实际结果、结果的时间或成就与这些前瞻性陈述中明示或暗示的信息存在重大差异。

We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. .

我们预计，随后发生的事件和发展可能会导致我们的预期和假设发生变化，我们没有义务更新或修改任何前瞻性声明，无论这是由于新信息、未来事件或其他原因所致，除非法律另有要求。

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.

除非法律明确要求，公司及其管理人员、董事、员工和代理人不对所提供信息中的前瞻性陈述的准确性和完整性承担责任。